Navigation Links
ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Date:8/28/2008

LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ --

- Professor Desire Collen Will Remain as Chairman of the Board and Scientific Advisor

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces today that Patrik De Haes, MD, currently Chief Operating Officer, has been appointed to succeed Professor Desire Collen as the Company's new Chief Executive Officer on September 1, 2008. At the next General Shareholders Meeting Dr. De Haes will be proposed to become a member of the Board of Directors of ThromboGenics. In the mean time, he will be invited to the Board meetings.

ThromboGenics will continue to benefit from Professor Collen's significant scientific and drug discovery knowledge. Professor Collen will remain Chairman of ThromboGenics' Board of Directors. This new structure ensures the continuity of ThromboGenics' senior management.

Dr. De Haes, 50, has considerable international experience across the biotechnology and healthcare sectors spanning more than 20 years. For the last 18 months, Dr. De Haes has been ThromboGenics' Chief Operating Officer overseeing the Company's daily operations. During this period, he has been a key member of the management team that has achieved a number of transforming milestones for ThromboGenics. These include initiating the clinical development of the Company's unique anti-cancer agent TB-403, and the subsequent development deal for potentially up to EUR500 million with Roche. Dr. De Haes has also been a major contributor to the development strategy of ThromboGenics' lead product, microplasmin, which the Company plans to advance into Phase III clinical trials in early 2009 for the treatment of a number of important eye diseases.

Prior to joining ThromboGenics, Dr. De Haes was Head of the Global Insulin Infusion Business at Roche Diagnostics in Bern, Switzerland, and a member of the Executive Commit
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
2. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
3. ThromboGenics N.V. - Business Update
4. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
5. ThromboGenics Announces 2007 Full Year Results
6. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
7. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
8. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
9. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
10. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
11. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... 2015 The 2015 Market Research ... a professional and in-depth study on the current ... with a focus on the Chinese situation. ... research are Linde Industrial Gas, Basf, Air Products, ... Xinlong Group, Longsheng Group, Juhua Group, Wandali Gas, ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 Phenome Networks, ... software provider, announced the availability, beginning May 31st, of ... version of Phenome One solidifies Phenome Networks’ lead in ... supporting a simple and intuitive breeding workflow based on ... ability to customize field design, and more. The new ...
(Date:5/22/2015)... plc (NYSE: ACT ) today confirmed that a ... Second Circuit has issued a ruling upholding a December ... distribution of NAMENDA ® (memantine HCl) immediate-release tablets. ... "While we are disappointed by the Court,s decision ... strong efforts to convey the significant benefits of NAMENDA ...
(Date:5/22/2015)... 22, 2015 According to a ... & 2D Gel Electrophoresis, Agarose & Polyacrylamide Gel, Capillary ... by Application & by End User - Global Forecast ... expected to reach around $1.98 Billion by 2020 with ... to 2020. Browse 226 ma ...
Breaking Biology Technology:Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 2Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4
... will have a new resource to help them navigate ... related centers on campus. , ,The Office of Corporate ... , which is to include events, publications and both ... to UW=-Madison faculty, staff and students. , ,Were one ...
... Santiago At the State University of New York in ... the campus that led to the creation of a $1.5 ... residence in Wisconsin, Santiago sees no reason why UW-Milwaukee can't ... this summer as the new chancellor of UW-Milwaukee, is determined ...
... Wis. The University of Wisconsin-Madison announced on Friday ... the field of stem-cell research. R. Timothy Mulcahy, a professor ... be leaving UW-Madison to become vice president of research at ... missed, graduate school Dean Martin Cadwallader said in a statement. ...
Cached Biology Technology:UW plans entrepreneurship program to link campus resources 2UW-Milwaukee Chancellor Santiago determined to build on research base 2UW-Milwaukee Chancellor Santiago determined to build on research base 3UW-Madison associate dean, active in stem cells, leaves 2
(Date:5/25/2015)... , May 25, 2015  Australia,s market for wearable ... although 2014 saw the advent of several trials and ... April 2015 is expected to ignite interest in wearables ... Australia . This in turn will ... and drive new partnerships amongst vendors and distributors. ...
(Date:5/22/2015)... CT , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... June 1st, it will be ending its promotional pricing and ... . Laurence Savin , Head of Marketing ... exclusive promotional pricing until the end of May. To get ... wocketwallet.com/invite and when we open the store on June 1, ...
(Date:5/22/2015)... , May 22, 2015 ... Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software ... User (Government and Utilities, Consumer and Home) - Global ... to grow from $2.77 Billion in 2015 to $6.19 ... Browse 79 market data Tables and   ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... major obstacle to HIV research is the virus,s exquisite specialisation ... like the humble lab mouse, can deliver only limited information. ... access Journal of Biology have made an ingenious ... key features of HIV infection without being infected with HIV. ...
... the Ocean,s most distinctive residents. ,Everyone wants to understand ... McComb from Florida Atlantic University. One possible reason is ... enhanced by their weird head shape, says McComb, giving ... to McComb, there were two schools of thought on ...
... are the bare essentials of life, the indispensable ingredients required ... Can we describe the molecular anatomy of a cell, and ... are just some of the questions that scientists in a ... Germany, and the Centre de Regulacio Genmica (CRG) in Barcelona, ...
Cached Biology News:A reductionist approach to HIV research 2Wide heads give hammerheads exceptional stereo view 2First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3
...
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
...
... Collect eliminates manual data entry by ... into any Windows-based application. Collect is ... countless hours of tedious data entry. ... balances, scales, pH meters, spectrophotometers, force gauges, ...
Biology Products: